Ocular Financial Statements From 2010 to 2024

OCUL Stock  USD 9.89  0.17  1.69%   
Ocular Therapeutix financial statements provide useful quarterly and yearly information to potential Ocular Therapeutix investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Ocular Therapeutix financial statements helps investors assess Ocular Therapeutix's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Ocular Therapeutix's valuation are summarized below:
Gross Profit
-6.5 M
Profit Margin
(2.26)
Market Capitalization
1.6 B
Enterprise Value Revenue
19.5759
Revenue
61.1 M
There are over one hundred nineteen available trending fundamental ratios for Ocular Therapeutix, which can be analyzed over time and compared to other ratios. We recommend to check out Ocular Therapeutix's recent fundamental drivers against the all of the trends between 2010 and 2024. The value of Market Cap is estimated to slide to about 238.3 M. The Enterprise Value is projected to slide to about 200.8 M

Ocular Therapeutix Total Revenue

61.37 Million

Check Ocular Therapeutix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ocular Therapeutix's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 11.9 M or Selling General Administrative of 19 M, as well as many indicators such as Price To Sales Ratio of 5.79, Dividend Yield of 0.0 or PTB Ratio of 4.1. Ocular financial statements analysis is a perfect complement when working with Ocular Therapeutix Valuation or Volatility modules.
  
Check out the analysis of Ocular Therapeutix Correlation against competitors.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

Ocular Therapeutix Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets126.8 M252.1 M104 M
Slightly volatile
Short and Long Term Debt Total87.6 M83.4 M34.3 M
Slightly volatile
Other Current Liabilities28.4 M27.1 M9.5 M
Slightly volatile
Total Current Liabilities36.6 M34.9 M14.9 M
Slightly volatile
Other Liabilities18.3 M22.8 M15 M
Slightly volatile
Property Plant And Equipment Net10 M18.2 M8.1 M
Slightly volatile
Accounts PayableM4.4 M2.5 M
Slightly volatile
Cash205.6 M195.8 M82.4 M
Slightly volatile
Non Current Assets Total11.8 M19.8 M9.5 M
Slightly volatile
Non Currrent Assets Other1.8 M1.6 M1.5 M
Slightly volatile
Other Assets0.951.01.6 M
Pretty Stable
Long Term Debt78.7 M74.9 M29.1 M
Slightly volatile
Cash And Short Term Investments103.6 M195.8 M85.4 M
Slightly volatile
Net Receivables27.5 M26.2 M7.5 M
Slightly volatile
Common Stock Shares Outstanding44.2 M85.6 M35.5 M
Slightly volatile
Liabilities And Stockholders Equity126.8 M252.1 M104 M
Slightly volatile
Non Current Liabilities Total69.6 M126 M64.4 M
Slightly volatile
Other Current Assets8.3 M7.9 M3.2 M
Slightly volatile
Other Stockholder Equity828.1 M788.7 M334.7 M
Slightly volatile
Total Liabilities86.2 M160.9 M78 M
Slightly volatile
Property Plant And Equipment Gross40.4 M38.5 M11.4 M
Slightly volatile
Total Current Assets243.8 M232.2 M103.1 M
Slightly volatile
Short Term Debt4.9 M3.2 M3.9 M
Pretty Stable
Property Plant Equipment7.1 M11.3 MM
Slightly volatile
Current Deferred Revenue242.2 K255 KM
Slightly volatile
Common Stock Total Equity5.3 K9.2 K4.4 K
Slightly volatile
Long Term Debt Total33.7 M62.1 M28.4 M
Slightly volatile
Capital Surpluse424.2 M750 M349.2 M
Slightly volatile
Inventory2.4 M2.3 M757 K
Slightly volatile
Deferred Long Term Liabilities6.9 M7.3 M10.6 M
Slightly volatile
Short and Long Term DebtM9.5 M5.8 M
Slightly volatile
Net Invested Capital105.4 M166.1 M72.4 M
Slightly volatile
Net Working Capital126.5 M197.3 M76.1 M
Slightly volatile
Capital Stock8.2 K12 K5.7 K
Slightly volatile
Capital Lease Obligations7.2 M8.5 M9.5 M
Slightly volatile

Ocular Therapeutix Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.6 MM1.3 M
Slightly volatile
Interest Expense11.9 M11.3 MM
Slightly volatile
Selling General Administrative19 M33.9 M15.3 M
Slightly volatile
Selling And Marketing Expenses42.6 M40.5 M16.4 M
Slightly volatile
Total Revenue61.4 M58.4 M16.4 M
Slightly volatile
Gross Profit55.8 M53.2 M14.6 M
Slightly volatile
Other Operating Expenses75.8 M140.8 M62 M
Slightly volatile
Research Development36.4 M61.1 M30.4 M
Slightly volatile
Cost Of Revenue5.5 M5.3 M1.7 M
Slightly volatile
Total Operating Expenses74 M135.5 M60.6 M
Slightly volatile
Preferred Stock And Other Adjustments8.8 K9.9 K10.8 K
Slightly volatile
Interest Income3.1 M2.9 M1.3 M
Very volatile
Reconciled Depreciation2.6 M2.5 MM
Slightly volatile

Ocular Therapeutix Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation18.7 M17.8 M7.6 M
Slightly volatile
Begin Period Cash Flow74 M104.1 M59.5 M
Slightly volatile
Depreciation1.8 MM1.5 M
Slightly volatile
Capital Expenditures6.4 M6.1 M2.4 M
Slightly volatile
Total Cash From Financing Activities178.3 M169.8 M66 M
Slightly volatile
End Period Cash Flow207.4 M197.6 M83.6 M
Slightly volatile
Sale Purchase Of Stock656 K851 K458.4 K
Slightly volatile
Change To Liabilities1.7 M1.2 M1.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.796.0919855
Slightly volatile
Days Sales Outstanding294163445
Slightly volatile
Stock Based Compensation To Revenue0.290.3056.4599
Slightly volatile
Capex To Depreciation1.82.04061.4995
Pretty Stable
EV To Sales3.964.1684451
Slightly volatile
Inventory Turnover2.022.29111.9945
Slightly volatile
Days Of Inventory On Hand201159278
Slightly volatile
Payables Turnover2.261.20321.7899
Pretty Stable
Sales General And Administrative To Revenue0.550.580733.2413
Slightly volatile
Research And Ddevelopement To Revenue0.991.044713.4687
Slightly volatile
Capex To Revenue0.09890.10424.8212
Slightly volatile
Cash Per Share3.852.45294.1369
Slightly volatile
Days Payables Outstanding2883037.2 K
Slightly volatile
Income Quality1.250.86991.4517
Pretty Stable
Current Ratio8.736.65517.8663
Pretty Stable
Receivables Turnover2.122.23243.486
Very volatile
Graham Number4.845.096916.4013
Slightly volatile
Capex Per Share0.09270.07630.0828
Pretty Stable
Revenue Per Share0.770.73210.2365
Slightly volatile
Interest Debt Per Share1.071.10051.0517
Slightly volatile
Debt To Assets0.220.30350.2535
Slightly volatile
Operating Cycle476323614
Slightly volatile
Days Of Payables Outstanding2883037.2 K
Slightly volatile
Ebt Per Ebit1.170.981.0609
Very volatile
Quick Ratio8.76.5897.838
Pretty Stable
Net Income Per E B T0.890.80.997
Very volatile
Cash Ratio5.985.61125.6698
Pretty Stable
Days Of Inventory Outstanding201159278
Slightly volatile
Days Of Sales Outstanding294163445
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.841.08671.0335
Pretty Stable
Fixed Asset Turnover3.373.20921.137
Slightly volatile
Debt Ratio0.220.30350.2535
Slightly volatile
Price Sales Ratio5.796.0919855
Slightly volatile
Asset Turnover0.240.23190.0849
Slightly volatile
Gross Profit Margin0.610.90960.6958
Slightly volatile

Ocular Therapeutix Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap238.3 M356 M259.4 M
Slightly volatile
Enterprise Value200.8 M243.6 M216.7 M
Slightly volatile

Ocular Fundamental Market Drivers

Cash And Short Term Investments195.8 M

Ocular Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ocular Therapeutix Financial Statements

Ocular Therapeutix investors utilize fundamental indicators, such as revenue or net income, to predict how Ocular Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue255 K242.2 K
Total Revenue58.4 M61.4 M
Cost Of Revenue5.3 M5.5 M
Stock Based Compensation To Revenue 0.30  0.29 
Sales General And Administrative To Revenue 0.58  0.55 
Research And Ddevelopement To Revenue 1.04  0.99 
Capex To Revenue 0.10  0.10 
Revenue Per Share 0.73  0.77 
Ebit Per Revenue(1.41)(1.48)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports:
Check out the analysis of Ocular Therapeutix Correlation against competitors.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.29)
Revenue Per Share
0.529
Quarterly Revenue Growth
0.083
Return On Assets
(0.22)
Return On Equity
(0.73)
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.